579 results on '"Meisel, Roland"'
Search Results
2. Vaccinations
3. Outcomes of HLA-mismatched HSCT with TCRαβ/CD19 depletion or post-HSCT cyclophosphamide for inborn errors of immunity
4. Influence of ATLG serum levels on CD3/CD19-depleted hematopoietic grafts and on immune recovery in pediatric haplo-HSCT
5. Autologous gene therapy for hemoglobinopathies: From bench to patient’s bedside
6. Second allogeneic stem cell transplantation can rescue a significant proportion of patients with JMML relapsing after first allograft
7. CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany
8. Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL – long-term follow-up from the prospective ALL-SCT 2003 trial
9. Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity: an EBMT IEWP study
10. HSCT using carrier donors for CD40L deficiency results in excellent immune function and higher CD40L expression in cTfh
11. Results of a multicenter phase I/II trial of TCRαβ and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients
12. Mesenchymal stem cells improve redox homeostasis and mitochondrial respiration in fibroblast cell lines with pathogenic MT-ND3 and MT-ND6 variants
13. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis
14. Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors
15. Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders
16. Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with chronic myeloid leukaemia: A prospective multicentre trial of the I‐BFM Study Group
17. Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
18. Exagamglogene Autotemcel for Severe Sickle Cell Disease
19. Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes
20. Interleukin-1 blockade in patients with Wiskott-Aldrich syndrome: a retrospective multinational case series
21. HLA-E expression constitutes a novel determinant for ALL disease monitoring following hematopoietic stem cell transplantation
22. Influence of ATLG serum levels on CD3/CD19-depleted hematopoietic grafts and on immune recovery in pediatric haplo-HSCT
23. Extended clinical and immunological phenotype and transplant outcome in CD27 and CD70 deficiency
24. Approaches for bridging therapy prior to chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic B-lineage leukaemia in children and young adults
25. Elimination of Vaso-Occlusive Crises after Exagamglogene Autotemcel in Patients with Severe Sickle Cell Disease
26. Transfusion Independence after Exagamglogene Autotemcel in Patients with Transfusion-Dependent β-Thalassemia
27. IDENTIFICATION OF FUNCTIONAL DEFECTS LEADING TO BONE MARROW FAILURE IN GATA2 DEFICIENCY
28. The regulatory effect of hyaluronan on human mesenchymal stem cells’ fate modulates their interaction with cancer cells in vitro
29. Supportive care during pediatric hematopoietic stem cell transplantation: beyond infectious diseases. A report from workshops on supportive care of the Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT)
30. Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (III) Impfen bei hämatologischen und onkologischen Erkrankungen (antineoplastische Therapie, Stammzelltransplantation), Organtransplantation und Asplenie
31. Hematopoietic stem cell transplantation for children with acute myeloid leukemia—results of the AML SCT-BFM 2007 trial
32. Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targets
33. Clearance of Hematologic Malignancies by Allogeneic Cytokine-Induced Killer Cell or Donor Lymphocyte Infusions
34. Corrigendum: Efficient in vitro generation of IL-22-secreting ILC3 from CD34+ hematopoietic progenitors in a human mesenchymal stem cell niche
35. Aktualisierte AWMF Leitlinie zur Diagnostik und Therapie der Langerhanszell Histiozytose (LCH) im Kindes- und Jugendalter
36. Erratum zu: Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (III) Impfen bei hämatologischen und onkologischen Erkrankungen (antineoplastische Therapie, Stammzelltransplantation), Organtransplantation und Asplenie
37. Presence of centromeric but absence of telomeric group B KIR haplotypes in stem cell donors improve leukaemia control after HSCT for childhood ALL
38. Publisher Correction: Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes
39. S270: TRANSFUSION INDEPENDENCE AFTER EXAGAMGLOGENE AUTOTEMCEL IN PATIENTS WITH TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA
40. PB2511: CLINICAL COMPLICATIONS AMONG PATIENTS WITH SICKLE CELL DISEASE WITH RECURRENT VASO-OCCLUSIVE CRISES IN GERMANY
41. P1464: CLINICAL COMPLICATIONS AMONG PATIENTS WITH TRANSFUSION-DEPENDENT BETA-THALASSEMIA IN GERMANY
42. S111: TREATMENT OF POST-TRANSPLANT RELAPSE IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH BCP ALL USING CD19-CAR-T: A EUROPEAN RETROSPECTIVE ANALYSIS OF REAL-WORLD DATA
43. Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial
44. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia
45. P22 - IDENTIFICATION OF FUNCTIONAL DEFECTS LEADING TO BONE MARROW FAILURE IN GATA2 DEFICIENCY
46. Secondary Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation for Sickle Cell Disease Inform Gene Therapy Approaches
47. Supplementary Table from The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets
48. Data from The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets
49. Supplementary Figure from The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets
50. Next-generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.